Hohl Benjamininsider trades
In SEC Form 4 filings, Hohl Benjamin is listed as CHIEF FINANCIAL OFFICER of Enliven Therapeutics, Inc. (ELVN). In the last 90 days, Hohl Benjamin sold $534.5K of Enliven Therapeutics, Inc. (ELVN) on the open market and bought none. All 4 sales were reported under a 10b5-1 trading plan.
Companies and roles
| Company | Role | Transactions | Last filed |
|---|---|---|---|
| ELVNEnliven Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | 8 | Oct 21 |
Cluster buys
No cluster buy in the last 90 days included a purchase by this insider (two or more insiders buying within 14 days).
Form 4 historysince 2026-09-21
| Company | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| ELVNEnliven Therapeutics, Inc. | Oct 19 | Oct 21 | M | 6,018 | $14.85 | $89,367 | 44,018 | Yes | Form 4 |
| ELVNEnliven Therapeutics, Inc. | Oct 19 | Oct 21 | S | 6,018 | $38.48 | Sale −$231,546 | 38,000 | Yes | Form 4 |
| ELVNEnliven Therapeutics, Inc. | Oct 19 | Oct 21 | M · derivative | 6,018 | $14.85 | $89,367 | 175,000 | Yes | Form 4 |
| ELVNEnliven Therapeutics, Inc. | Sep 17 | Sep 21 | M | 3,982 | $14.85 | $59,133 | 44,018 | Yes | Form 4 |
| ELVNEnliven Therapeutics, Inc. | Sep 17 | Sep 21 | S | 3,535 | $50.03 | Sale −$176,851 | 40,483 | Yes | Form 4 |
| ELVNEnliven Therapeutics, Inc. | Sep 17 | Sep 21 | S | 2,194 | $50.72 | Sale −$111,270 | 38,289 | Yes | Form 4 |
| ELVNEnliven Therapeutics, Inc. | Sep 17 | Sep 21 | S | 289 | $51.49 | Sale −$14,881 | 38,000 | Yes | Form 4 |
| ELVNEnliven Therapeutics, Inc. | Sep 17 | Sep 21 | M · derivative | 3,982 | $14.85 | $59,133 | 181,018 | Yes | Form 4 |
Published from this insider's public Form 4 filings on SEC EDGAR; the name is shown as filed. Named in a filing and want this page removed? See the privacy policy.